Atea Net Income vs Cost Of Revenue Analysis

AVIR Stock

USD 3.37 0.12 3.69%

Atea Pharmaceuticals financial indicator trend analysis is way more than just evaluating Atea Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Atea Pharmaceuticals is a good investment. Please check the relationship between Atea Pharmaceuticals Net Income and its Cost Of Revenue accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atea Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Atea Stock, please use our How to Invest in Atea Pharmaceuticals guide.

Net Income vs Cost Of Revenue

Net Income vs Cost Of Revenue Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Atea Pharmaceuticals Net Income account and Cost Of Revenue. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Atea Pharmaceuticals' Net Income and Cost Of Revenue is -0.7. Overlapping area represents the amount of variation of Net Income that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of Atea Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Atea Pharmaceuticals' Net Income and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income of Atea Pharmaceuticals are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Net Income i.e., Atea Pharmaceuticals' Net Income and Cost Of Revenue go up and down completely randomly.

Correlation Coefficient

-0.7

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in Atea Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Atea Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.

Cost Of Revenue

Cost of Revenue is found on Atea Pharmaceuticals income statement and represents the costs associated with goods and services Atea Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most indicators from Atea Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Atea Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atea Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product.

To learn how to invest in Atea Stock, please use our How to Invest in Atea Pharmaceuticals guide.As of 11/24/2024, Selling General Administrative is likely to drop to about 31.8 M. In addition to that, Tax Provision is likely to drop to about 967.1 K

	2021	2022	2023	2024 (projected)
Interest Income	213K	11.2M	29.2M	30.7M
Net Interest Income	213K	11.2M	29.2M	30.7M

Interest Income Net Interest Income

Atea Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Capital Stock
Total Assets		0.82	0.69	0.98	0.73	0.96	0.55	0.52	-0.89	-0.24	0.69	0.89	0.58	0.57	0.4	1.0	0.97	0.85	-0.98	0.99	0.95	0.39	0.98	0.57	1.0	0.97
Other Current Liab	0.82		0.32	0.87	0.83	0.87	0.39	0.1	-0.69	-0.05	0.91	0.69	0.43	0.43	0.24	0.83	0.83	0.76	-0.82	0.85	0.65	0.01	0.87	0.42	0.82	0.84
Total Current Liabilities	0.69	0.32		0.53	0.06	0.5	0.01	0.97	-0.72	-0.11	0.01	0.72	0.01	0.02	-0.04	0.69	0.56	0.48	-0.61	0.61	0.85	0.94	0.53	0.01	0.69	0.56
Total Stockholder Equity	0.98	0.87	0.53		0.84	0.99	0.64	0.34	-0.85	-0.24	0.8	0.84	0.67	0.66	0.49	0.98	0.98	0.86	-0.98	1.0	0.88	0.2	1.0	0.65	0.98	0.99
Other Liab	0.73	0.83	0.06	0.84		0.84	0.8	-0.17	-0.46	-0.43	0.93	0.45	0.83	0.84	0.4	0.73	0.79	0.76	-0.82	0.79	0.55	-0.29	0.84	0.83	0.73	0.83
Net Tangible Assets	0.96	0.87	0.5	0.99	0.84		0.66	0.32	-0.79	-0.3	0.84	0.79	0.68	0.68	0.44	0.96	0.99	0.85	-0.97	0.98	0.87	0.17	0.99	0.67	0.96	0.99
Property Plant And Equipment Net	0.55	0.39	0.01	0.64	0.8	0.66		-0.13	-0.25	-0.69	0.61	0.25	1.0	0.99	0.54	0.55	0.64	0.59	-0.67	0.6	0.47	-0.28	0.64	1.0	0.55	0.68
Current Deferred Revenue	0.52	0.1	0.97	0.34	-0.17	0.32	-0.13		-0.62	-0.03	-0.21	0.61	-0.14	-0.13	-0.08	0.52	0.39	0.3	-0.43	0.43	0.73	0.98	0.34	-0.14	0.52	0.37
Net Debt	-0.89	-0.69	-0.72	-0.85	-0.46	-0.79	-0.25	-0.62		-0.19	-0.46	-1.0	-0.28	-0.24	-0.54	-0.89	-0.81	-0.69	0.81	-0.87	-0.85	-0.5	-0.85	-0.24	-0.89	-0.79
Retained Earnings	-0.24	-0.05	-0.11	-0.24	-0.43	-0.3	-0.69	-0.03	-0.19		-0.24	0.19	-0.68	-0.74	0.19	-0.23	-0.32	-0.34	0.38	-0.24	-0.33	0.01	-0.24	-0.72	-0.24	-0.37
Accounts Payable	0.69	0.91	0.01	0.8	0.93	0.84	0.61	-0.21	-0.46	-0.24		0.46	0.65	0.65	0.33	0.69	0.79	0.71	-0.73	0.75	0.47	-0.33	0.8	0.64	0.69	0.79
Cash	0.89	0.69	0.72	0.84	0.45	0.79	0.25	0.61	-1.0	0.19	0.46		0.27	0.23	0.54	0.89	0.81	0.68	-0.8	0.87	0.85	0.5	0.84	0.24	0.89	0.79
Non Current Assets Total	0.58	0.43	0.01	0.67	0.83	0.68	1.0	-0.14	-0.28	-0.68	0.65	0.27		0.99	0.54	0.57	0.66	0.62	-0.69	0.63	0.48	-0.28	0.67	1.0	0.57	0.7
Non Currrent Assets Other	0.57	0.43	0.02	0.66	0.84	0.68	0.99	-0.13	-0.24	-0.74	0.65	0.23	0.99		0.45	0.56	0.66	0.6	-0.69	0.62	0.49	-0.27	0.66	1.0	0.57	0.7
Other Assets	0.4	0.24	-0.04	0.49	0.4	0.44	0.54	-0.08	-0.54	0.19	0.33	0.54	0.54	0.45		0.4	0.43	0.35	-0.38	0.45	0.26	-0.23	0.49	0.48	0.4	0.41
Cash And Short Term Investments	1.0	0.83	0.69	0.98	0.73	0.96	0.55	0.52	-0.89	-0.23	0.69	0.89	0.57	0.56	0.4		0.96	0.85	-0.98	0.99	0.95	0.39	0.98	0.56	1.0	0.97
Common Stock Total Equity	0.97	0.83	0.56	0.98	0.79	0.99	0.64	0.39	-0.81	-0.32	0.79	0.81	0.66	0.66	0.43	0.96		0.84	-0.97	0.98	0.9	0.23	0.98	0.65	0.96	1.0
Common Stock Shares Outstanding	0.85	0.76	0.48	0.86	0.76	0.85	0.59	0.3	-0.69	-0.34	0.71	0.68	0.62	0.6	0.35	0.85	0.84		-0.87	0.87	0.78	0.19	0.86	0.61	0.85	0.86
Non Current Liabilities Total	-0.98	-0.82	-0.61	-0.98	-0.82	-0.97	-0.67	-0.43	0.81	0.38	-0.73	-0.8	-0.69	-0.69	-0.38	-0.98	-0.97	-0.87		-0.99	-0.93	-0.3	-0.98	-0.68	-0.98	-0.98
Other Current Assets	0.99	0.85	0.61	1.0	0.79	0.98	0.6	0.43	-0.87	-0.24	0.75	0.87	0.63	0.62	0.45	0.99	0.98	0.87	-0.99		0.92	0.3	1.0	0.61	0.99	0.98
Other Stockholder Equity	0.95	0.65	0.85	0.88	0.55	0.87	0.47	0.73	-0.85	-0.33	0.47	0.85	0.48	0.49	0.26	0.95	0.9	0.78	-0.93	0.92		0.62	0.88	0.48	0.95	0.9
Total Liab	0.39	0.01	0.94	0.2	-0.29	0.17	-0.28	0.98	-0.5	0.01	-0.33	0.5	-0.28	-0.27	-0.23	0.39	0.23	0.19	-0.3	0.3	0.62		0.2	-0.27	0.39	0.23
Net Invested Capital	0.98	0.87	0.53	1.0	0.84	0.99	0.64	0.34	-0.85	-0.24	0.8	0.84	0.67	0.66	0.49	0.98	0.98	0.86	-0.98	1.0	0.88	0.2		0.65	0.98	0.99
Property Plant And Equipment Gross	0.57	0.42	0.01	0.65	0.83	0.67	1.0	-0.14	-0.24	-0.72	0.64	0.24	1.0	1.0	0.48	0.56	0.65	0.61	-0.68	0.61	0.48	-0.27	0.65		0.56	0.69
Total Current Assets	1.0	0.82	0.69	0.98	0.73	0.96	0.55	0.52	-0.89	-0.24	0.69	0.89	0.57	0.57	0.4	1.0	0.96	0.85	-0.98	0.99	0.95	0.39	0.98	0.56		0.97
Capital Stock	0.97	0.84	0.56	0.99	0.83	0.99	0.68	0.37	-0.79	-0.37	0.79	0.79	0.7	0.7	0.41	0.97	1.0	0.86	-0.98	0.98	0.9	0.23	0.99	0.69	0.97

Click cells to compare fundamentals

Atea Pharmaceuticals Account Relationship Matchups

Atea Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	22.1M	863.6M	772.9M	666.7M	595.0M	541.8M
Other Current Liab	1.9M	14.4M	49.6M	14.4M	27.4M	20.0M
Total Current Liabilities	2.4M	315.8M	56.9M	18.5M	32.4M	57.0M
Total Stockholder Equity	(49.6M)	547.8M	710.1M	640.6M	555.2M	434.1M
Other Liab	95K	36K	5.9M	5.3M	6.0M	6.3M
Net Tangible Assets	(49.6M)	547.8M	710.1M	640.6M	736.7M	398.8M
Property Plant And Equipment Net	41K	48K	23K	4.1M	3.1M	3.3M
Net Debt	(21.7M)	(850.1M)	(764.2M)	(643.6M)	(141.4M)	(148.5M)
Retained Earnings	(54.2M)	(65.2M)	56.0M	(59.9M)	(195.8M)	(186.0M)
Accounts Payable	548K	60K	4.5M	2.6M	4.3M	2.3M
Cash	21.7M	850.1M	764.4M	646.7M	143.8M	136.6M
Cash And Short Term Investments	21.7M	850.1M	764.4M	646.7M	578.1M	530.8M
Common Stock Shares Outstanding	82.6M	82.4M	88.2M	83.2M	83.4M	85.7M
Liabilities And Stockholders Equity	22.1M	863.6M	772.9M	666.7M	595.0M	541.8M
Non Current Liabilities Total	69.2M	36K	5.9M	7.7M	7.4M	7.0M
Other Current Assets	249K	15.1M	16.1M	14.2M	12.3M	10.7M
Other Stockholder Equity	4.6M	1.5B	654.0M	701.1M	750.7M	658.3M
Total Liab	71.6M	315.8M	62.8M	26.1M	39.8M	78.3M
Net Invested Capital	(49.6M)	547.8M	710.1M	640.6M	555.2M	434.1M
Property Plant And Equipment Gross	41K	48K	184K	4.4M	3.8M	4.0M
Total Current Assets	21.9M	863.5M	772.4M	660.9M	590.5M	539.7M
Net Working Capital	19.5M	547.7M	715.5M	642.4M	558.1M	461.3M
Property Plant Equipment	41K	48K	23K	4.1M	4.7M	4.9M

Pair Trading with Atea Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Atea Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Atea Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving together with Atea Stock

0.71	VALN	Valneva SE ADR	Pair Corr
0.63	VCNX	Vaccinex	Pair Corr

Moving against Atea Stock

0.72	BMY	Bristol Myers Squibb Aggressive Push	Pair Corr
0.62	EWTX	Edgewise Therapeutics	Pair Corr
0.61	GILD	Gilead Sciences	Pair Corr
0.48	KZR	Kezar Life Sciences	Pair Corr
0.45	VRDN	Viridian Therapeutics	Pair Corr

The ability to find closely correlated positions to Atea Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Atea Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Atea Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Atea Pharmaceuticals to buy it.

The correlation of Atea Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Atea Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Atea Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Atea Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Additional Tools for Atea Stock Analysis

When running Atea Pharmaceuticals' price analysis, check to measure Atea Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atea Pharmaceuticals is operating at the current time. Most of Atea Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Atea Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atea Pharmaceuticals' price. Additionally, you may evaluate how the addition of Atea Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC